New concepts in pathogenesis and treatment of diabetic retinopathy

Experimental and Clinical Endocrinology and Diabetes

Volumn 109, Issue SUPPL. 2, 2001, Pages

  Spranger, J ^a   Pfeiffer, A F H ^a  

^a GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

Author keywords

Angiogenesis; Cytokine; Diabetes; Growth factor; Neovascularization; Retinopathy

Indexed keywords

ANGIOGENESIS; ARTICLE; BLINDNESS; DIABETIC RETINOPATHY; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; RETINA NEOVASCULARIZATION;

ANIMALS; DIABETIC RETINOPATHY; ENDOTHELIAL GROWTH FACTORS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LYMPHOKINES; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034948833     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-18601     Document Type: Article

References (76)

1. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders
2. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins
3. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor
4. The rising global burden of diabetes and its complications: Estimates and projections to the year 2010
5. An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes
6. Transforming growth factor beta in disease: The dark side of tissue repair
7. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications
8. Diabetic retinopathy: A further study of prognosis for vision
9. Evidence that upregulation of serum IGF-I concentration causes acceleration of diabetic retinopathy
10. Metabolic control and progression of retinopathy
11. The effect of intensive diabetes treatment on the development and progression of long-term complications ininsulin-dependent diabetes mellitus: The Diabetes Control and Complications Trial
12. Photocoagulation treatment of proliferative diabetic retinopathy: Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8
13. Association of elevated IGF-I levels with increased retinopathy in late onset diabetes
14. Insulin and Insulin-like growth factors in diabetes mellitus
15. Photocoagulation for diabetic macular edema: Early Treatment Retinopathy Study report number 1
16. Classification of diabetic retinpathy from fluorescein angiograms. ETDRS Report Number 11.
17. Early Photocoagulation for Diabetic Retinopathy: ETDRS Report Number 9.
18. Fundus photographic risk factors for progression of diabetic retinopathy
19. Experimental galactosemia produces diabetic-like retinopathy
20. Hypoxia upregulates the synthesis of TGF-beta 1 by human dermal fibroblasts
21. Molecular and biological properties of the vascular endothelial growth factor family of proteins
22. Localization and actions of transforming growth factor-beta in the embryonic nervous system
23. Angiogenesis
24. Galactose induced retinal basement membrane thickening: Prevention by sorninil
25. Plasminogen activator production by human retinal endothelial cells of nondiabetic and diabetic origin
26. Insulin-like growth factors in the vitreous: Studies in control and diabetic subjects with neovascularisation
27. Increased serum levels of vascular endothelial growth factor in patients with inflammatory bowel disease
28. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization
29. Treatment with insulin-like growth factor I alters capillary permeability in skin and retina
30. Serum IGF-I concentration in diabetic retinopathy
31. Amelioration of vascular dysfunction in diabetic rats by an oral PKC beta inhibitor
32. Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis
33. Prevalence of diabetic retinpathy: Age, sex and duration of diabetes
34. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumour growth in vivo
35. Pigment-Epithelium-Derived Factor: A key coordinator of retinal neuronal and vascular functions
36. Prevalence of cataracts in a population-based study of persons with diabetes mellitus
37. Incidence of cataract surgery in the Wisconsin Epidemiologic Study of Diabetic Retinopathy
38. Older-onset diabetes and lens opacities: The Beaver Dam Eye Study
39. Microaneurysms in the development of diabetic retinopathy (UKPDS 42)
40. Von Willebrand factor, fibronectin and insulin-like growth factors I and II in diabetic retinopathy and nephropathy
41. Differential regulation of protein kinase C and (Na,K)-adenosine triphosphatase activities by elevated glucose levels in retinal capillary endothelial cells
42. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin
43. A follow-up study of vascular disease in growth hormone deficient dwarfs with diabetes
44. Diabetes mellitus and sexual ateliotic dwarfism: A comparative study
45. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects
46. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation
47. Vascular endothelial growth factor (VEGF) and its receptors
48. Macular edema - An overlooked complication of diabetic retinopathy
49. Elevated plasma levels of transforming growth factor-β In NIDDM
50. Growth factor alterations in advanced diabetic retinopathy. A possible role of blood retina barrier breakdown
51. mRNA expression of ligands of the epidermal-growth-factor-receptor in the uterus
52. Diabetes and anterior pituitary deficiency
53. Factors influencing the development of visual loss in advanced diabetic retinopathy: Diabetic Retinopathy (DRS) report no. 10
54. Retinal capillaries: Basement membrane thickening by galactosaemia prevented by aldose reductase inhibitor
55. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: Activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture
56. Growth factors in the pathogenesis of diabetic retinopathy
57. Long term follow-up of patients who underwent yttrium-90 pituitary imlantation for treatment of proliferative diabetic retinopathy
58. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
59. Vitrectomy for complications of proliferative diabetic retinopathy: Functional outcomes
60. Essential role of growth hormone in ischemia-induced retinal neovascularization
61. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor
62. A randomized trial of sorminil, an aldose reductase inhibitor, in diabetic retinopathy
63. TNF-alpha-Spiegel im Glaskörper: Anstieg bei neovaskulären Augenkrankheiten und proliferativer diabetischer Retinopathie
64. Deficient activation and different expression of transforming growth factor-β isoforms in active proliferative diabetic retinopathy and neovascular eye disease
65. Release of the angiogenesis inhibitor angiostatin in patients with proliferative diabetic retinopathy: Association with retinal photocoagulation
66. Systemic levels contribute significantly to increased levels of IGF-I, -II and IGF-BP3 in proliferative diabetic retinopathy
67. Early worsening of diabetic retinopathy in the Diabetes Control and Complication Trial
68. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy
69. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
70. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38)
71. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes
72. Electron microscopic immunocytochemical demonstration of blood-retinal barrier breakdown in human diabetics and its association with aldose reductase in retinal vascular epithelium and retinal pigment epithelium
73. High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-beta
74. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy
75. Ocular pathology of diabetes
76. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta